Shares of Hims & Hers Health Inc. (HIMS) surged 9.78% in pre-market trading on November 5, 2024, after the telehealth platform reported outstanding third-quarter results and raised its full-year guidance.
For the quarter ended September 30, 2024, Hims & Hers posted revenue of $401.6 million, up a staggering 77% year-over-year, driven by strong growth in online sales of prescription medications and health and wellness products. The company swung to a net income of $75.6 million from a loss in the prior-year period, thanks to a $60.8 million tax benefit.
Hims & Hers' weight-loss solutions, particularly its compounded versions of GLP-1 medications like semaglutide, were a major growth catalyst. The company said its personalized dosing regimens resonated well with customers, with 90% of surveyed users expressing satisfaction and 87% progressing towards or achieving their weight-loss goals.
Buoyed by the impressive performance, the company raised its full-year 2024 revenue guidance to a range of $1.46 billion to $1.465 billion, up from its previous estimate of $1.37 billion to $1.4 billion. Hims & Hers also boosted its adjusted EBITDA guidance to $173 million to $178 million, reflecting an expected 12% adjusted EBITDA margin.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.